INSMED Inc

Insmed reported strong financial results for the second quarter of 2026, with total revenues surging to $425.5 million, driven by robust sales of BRINSUPRI and ARIKAYCE. The company significantly reduced its net loss to $13.2 million and raised its full-year 2026 BRINSUPRI revenue guidance to $1.25 billion to $1.40 billion. Additionally, Insmed increased its total peak revenue estimate for its three lead programs to over $14 billion and made progress on pipeline initiatives, including filing an sNDA for ARIKAYCE and advancing TPIP and INS1033 clinical programs.

Insmed reported a substantial increase in product revenues for the second quarter and first half of 2026, primarily driven by the strong performance of BRINSUPRI following its recent approvals. The company's net loss significantly narrowed compared to the same periods last year, reflecting improved financial performance. These results highlight the successful commercialization efforts and pipeline advancements.

INSMED Inc. announced positive 12-month safety and efficacy data from its ongoing open-label extension (OLE) study of treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH). The data demonstrated sustained improvement across all secondary efficacy measures, including a reduction in mortality risk status as measured by REVEAL Lite 2.0. TPIP was found to be safe and well-tolerated with no new safety signals identified, reinforcing its potential as a once-daily prostanoid for PAH patients. The company is advancing its Phase 3 PALM-PAH study.

Insmed Incorporated reported strong financial results for the first quarter ended March 31, 2026, with total company revenues reaching $306.0 million. BRINSUPRI revenues surged 44% sequentially to $207.9 million, while ARIKAYCE revenues grew 6% year-over-year to $98.1 million. The company also announced positive topline results from the Phase 3b ENCORE study for ARIKAYCE and the initiation of the Phase 3 PALM-PAH study for TPIP, while reiterating its full-year 2026 revenue guidance for both key products.

Insmed reported a significant increase in product revenues for Q1 2026, reaching $305.96 million, up from $92.82 million in Q1 2025. The company's net loss narrowed to $163.56 million, or $(0.76) per share, compared to a net loss of $256.58 million, or $(1.42) per share, in the prior year period. This revenue growth was primarily driven by the commercial launch of BRINSUPRI, which generated $207.18 million in US sales. Despite improved financial performance, Insmed expects to continue incurring operating losses due to ongoing research and development activities and commercialization efforts for its product pipeline.

INSMED Incorporated announced topline efficacy and safety results from its Phase 2b CEDAR study evaluating brensocatib in patients with moderate to severe hidradenitis suppurativa (HS). The study failed to meet its primary endpoint, as both brensocatib treatment arms demonstrated a lesser reduction in abscess and inflammatory nodule (AN) count compared to the placebo arm at Week 16. Specifically, the brensocatib 10 mg and 40 mg arms achieved 45.5% and 40.3% reductions in AN count, respectively, while the placebo arm showed a more significant 57.1% reduction. This outcome represents a significant setback for brensocatib's development in HS, potentially impacting the drug's future in this indication and the company's pipeline valuation.